Media

GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

Lilotomab pre-dosing of NHL patients before Betalutin® therapy lowers haematological toxicity with no reduction in the tumor absorbed radiation dose

Single stage surgical procedure achieves 96% infection eradication rate

GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa

Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology (ESC) Congress 2016

Completion of patient enrolment in the CARAT study – meeting the clinical schedule

NORDIC NANOVECTOR ASA – RESULTS FOR SECOND QUARTER AND HALF YEAR 2016

RSPR Pharma hires Paul de Potocki as Chief Business Officer